SIGN UP FOR THE WEBINAR

How to commercialize a new strain
as a probiotic

 

Speaker: 
Johanna Maukonen, D.Sc. (Tech)
Global Director of Clinical Innovation and Translation
IFF Health Sciences

Johanna will be talking about the path that is needed to commercialize a new strain as a probiotic. Starting from isolation of the strain from e.g.a clinical study, through strain characterization and safety assessments to move forward with manufacturing optimization, while also looking at the health efficacy potential from preclinical studies to human clinicals.
biosafe_webinar_12-6-2025_How-to-commercialize-a-new-strain-as-a-probiotic

Update your knowledge and sign up for the webinar
June 12, 2025

10 AM EET (Eastern Europe)
9 AM CEST (Central Europe)

Our webinars are open and free for everyone. Webinar recordings will be available for all registered participants.

Introduction

Biosafe's webinars are open and free for everyone interested in regulatory, safety or scientific issues surrounding regulated microbial products used in food and feed. Our webinars promote discussions, educate professionals and bring out interesting technologies or standards in the field. We welcome your ideas for future topics too.
Tune in and enjoy!

If you have technical problems, please contact Teemu Kuhmonen.

Program and schedule

8.55 AM CEST (Central European Time)
Welcome and webinar instructions.
Please join the webinar to make sure the connection works.

9.00 - 10.00 AM CEST (Central European Time)

How to commercialize a new strain as a probiotic

Speaker: 
Johanna Maukonen, D.Sc. (Tech)
Global Director of Clinical Innovation and Translation
IFF Health Sciences

Johanna leads Global Clinical Innovation and Translation, being a key link for Health R&D to customers and external scientific communities. Previously, she led Global Health and Nutrition Science group, which conducted and coordinated in vitro, pre-clinical and clinical studies on IFF’s ingredients. Before joining IFF, Johanna worked for over 20 years at VTT Technical Research Centre, Finland. She has extensive R&D experience in understanding the gut microbiota and its impact on health, especially on the influence of probiotics, nutrition and fibres.

Johanna will be talking about the path that is needed to commercialize a new strain as a probiotic. Starting from isolation of the strain from e.g.a clinical study, through strain characterization and safety assessments to move forward with manufacturing optimization, while also looking at the health efficacy potential from preclinical studies to human clinicals.
sign up for the webinar

Share in social media:

Organized by:


Logo-Biosafe-black-and-green

 

More information

Pauliina Halimaa, Managing Director, Biosafe
pauliina.halimaa@biosafe.fi
+35840 640 3225

New call-to-action

Biosafe Ltd is testing laboratory No. T356 accredited by FINAS Finnish Accreditation Service, accreditation requirement SFS-EN ISO/IEC 17025 (see accreditation certificate). Information on the activities within the scope of the accreditation is available at www.finas.fi